ETON Eton Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1710340 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY100.6%
TTM net income YoY846.2%
TTM EPS YoY703.3%
Revenue 3-yr CAGR62.6%
Net income 3-yr CAGR181.6%
Margins
Gross margin69.2%
Operating margin28.8%
Net margin35.3%
FCF margin27.1%
EBITDA margin31.4%
Returns
ROE90.6%
ROA38.1%
ROIC (approx.)115.0%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets44.7%
Debt / equity0.27x
Current ratio1.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio8.8%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $79.95M | $39.01M | $31.64M | $21.25M | $21.83M |
| Cost of revenue | $37.21M | $15.60M | $10.58M | $6.93M | $2.83M |
| Gross profit | $42.74M | $23.41M | $21.06M | $14.32M | $19.00M |
| R&D expense | $7.76M | $3.25M | $3.32M | $4.00M | $6.24M |
| SG&A expense | $35.82M | $22.75M | $18.93M | $18.58M | $14.27M |
| Operating income | -$844,000 | -$2.60M | -$1.19M | -$8.26M | -$1.50M |
| Interest expense | $4.78M | $2.00M | $1.06M | $955,000 | $1.04M |
| Pretax income | -$4.56M | -$3.81M | -$689,000 | -$9.02M | -$1.96M |
| Income tax | $43,000 | $15,000 | $247,000 | $0 | $0 |
| Net income | -$4.60M | -$3.82M | -$936,000 | -$9.02M | -$1.96M |
| EBITDA | $3.20M | -$1.45M | -$291,000 | -$6.49M | -$1.03M |
| EPS (basic) | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 |
| EPS (diluted) | — | — | — | — | -0.08 |
| Weighted avg. shares (diluted) | — | — | — | — | 25.21M |
| Balance sheet | |||||
| Cash & equivalents | $25.94M | $14.94M | $21.39M | $16.30M | $14.41M |
| Receivables | $11.76M | $5.36M | $3.41M | $1.85M | $5.47M |
| Inventory | $15.42M | $15.23M | $911,000 | $557,000 | $550,000 |
| Current assets | $60.58M | $41.02M | $26.84M | $20.00M | $23.60M |
| PP&E, net | $326,000 | $34,000 | $58,000 | $72,000 | $115,000 |
| Intangibles | $30.88M | $34.88M | $4.74M | $4.75M | $3.62M |
| Total assets | $92.11M | $76.12M | $31.74M | $25.03M | $27.46M |
| Current liabilities | $38.49M | $19.95M | $16.24M | $6.46M | $4.56M |
| Short-term debt | $8.79M | $0 | $5.38M | $1.03M | $1.42M |
| Long-term debt | $21.77M | $29.81M | $0 | $5.38M | $5.26M |
| Total debt | $30.56M | $29.81M | $5.38M | $6.42M | $6.68M |
| Total liabilities | $65.96M | $51.70M | $16.26M | $11.95M | $9.84M |
| Shareholders' equity | $26.15M | $24.43M | $15.48M | $13.08M | $17.63M |
| Net debt | $4.62M | $14.88M | -$16.01M | -$9.89M | -$7.73M |
| Shares outstanding | 27.05M | 26.71M | 25.69M | 25.35M | 24.63M |
| Cash flow statement | |||||
| Operating cash flow | $10.52M | $969,000 | $6.82M | $4.82M | -$4.72M |
| Capital expenditure | $333,000 | $26,000 | $0 | $38,000 | $9,000 |
| Free cash flow | $10.19M | $943,000 | $6.82M | $4.78M | -$4.73M |
| Investing cash flow | -$333,000 | -$40.01M | -$775,000 | -$2.79M | -$2.56M |
| Financing cash flow | $815,000 | $32.59M | -$957,000 | -$134,000 | $391,000 |
| Depreciation & amortization | $4.04M | $1.15M | $901,000 | $1.77M | $462,000 |
| Stock-based compensation | $5.51M | $3.17M | $3.14M | $4.22M | $3.38M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.